These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 25998298)

  • 41. DPP-4 Inhibitor Linagliptin Attenuates Aβ-induced Cytotoxicity through Activation of AMPK in Neuronal Cells.
    Kornelius E; Lin CL; Chang HH; Li HH; Huang WN; Yang YS; Lu YL; Peng CH; Huang CN
    CNS Neurosci Ther; 2015 Jul; 21(7):549-57. PubMed ID: 26010513
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes.
    Saulsberry WJ; Coleman CI; Mearns ES; Zaccaro E; Doleh Y; Sobieraj DM
    Int J Clin Pract; 2015 Nov; 69(11):1221-35. PubMed ID: 26215321
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option.
    Woo V
    Int J Clin Pract; 2015 Dec; 69(12):1427-37. PubMed ID: 26303997
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis.
    Kalra S; Sahay R; Gupta Y
    Indian J Endocrinol Metab; 2015; 19(4):524-8. PubMed ID: 26180770
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers.
    Macha S; Mattheus M; Pinnetti S; Broedl UC; Woerle HJ
    Clin Ther; 2015 Jul; 37(7):1503-16. PubMed ID: 26051874
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
    Tinahones FJ; Gallwitz B; Nordaby M; Götz S; Maldonado-Lutomirsky M; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2017 Feb; 19(2):266-274. PubMed ID: 27762093
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Liraglutide improves hypertension and metabolic perturbation in a rat model of polycystic ovarian syndrome.
    Hoang V; Bi J; Mohankumar SM; Vyas AK
    PLoS One; 2015; 10(5):e0126119. PubMed ID: 26010091
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.
    Blonde L; Jendle J; Gross J; Woo V; Jiang H; Fahrbach JL; Milicevic Z
    Lancet; 2015 May; 385(9982):2057-66. PubMed ID: 26009229
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Weight management in Ramadan.
    Sethi BK; Nagesh VS
    J Pak Med Assoc; 2015 May; 65(5 Suppl 1):S54-6. PubMed ID: 26013789
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
    Pieber TR; Famulla S; Eilbracht J; Cescutti J; Soleymanlou N; Johansen OE; Woerle HJ; Broedl UC; Kaspers S
    Diabetes Obes Metab; 2015 Oct; 17(10):928-35. PubMed ID: 26080652
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
    Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
    Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus: post hoc subgroup analyses according to body mass index in a 52-week open-label study.
    Inagaki N; Goda M; Yokota S; Maruyama N; Iijima H
    Expert Opin Pharmacother; 2015; 16(11):1577-91. PubMed ID: 26104600
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
    Ferrannini E; DeFronzo RA
    Eur Heart J; 2015 Sep; 36(34):2288-96. PubMed ID: 26063450
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial.
    Hong AR; Lee J; Ku EJ; Hwangbo Y; Kim KM; Moon JH; Choi SH; Jang HC; Lim S
    Diabetes Res Clin Pract; 2015 Jul; 109(1):141-8. PubMed ID: 26003889
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Challenges in pharmacotherapeutics education for diabetes in real-world clinical settings: views from family medicine and internal medicine residents.
    Farahani P
    Clin Invest Med; 2015 May; 38(3):E73-81. PubMed ID: 26026641
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial.
    Kothny W; Lukashevich V; Foley JE; Rendell MS; Schweizer A
    Diabetologia; 2015 Sep; 58(9):2020-6. PubMed ID: 26067186
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.
    Devineni D; Polidori D
    Clin Pharmacokinet; 2015 Oct; 54(10):1027-41. PubMed ID: 26041408
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
    Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
    Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.